Customer
Case Study
Biotechnology · Drug Discovery

Nanomedical Diagnostics partners with Rogue Valley Microdevices to bring the world’s first commercial graphene biosensor to scale

How a collaborative MEMS foundry partnership solved the challenge of integrating defect-free graphene into high-volume manufacturing—bringing the label-free Agile R100 binding assay to market.

AGILE R100
Field Effect Biosensing

The world’s first commercial graphene biosensor — a label-free kinetic binding assay.

Researcher holding the Agile R100 device
Customer
Nanomedical Diagnostics
Agile R100 · Field Effect Biosensing
Industry
Biotechnology · drug discovery & biotherapeutics
Challenge
Integrating defect-free graphene into standard high-volume MEMS production
Solution
A co-developed fabrication flow pairing RVM MEMS processing with graphene growth
Value of RVM’s role
Novel capping & passivation, process rigor, reproducibility, and high throughput
Why field effect biosensing
World’s first commercial graphene biosensor
Label-free kinetic binding assay
Small molecules, no lower size limit
A fraction of the cost and size
An electrical alternative to the costly SPR and BLI tools used in drug discovery today.
01

Transforming drug discovery with a graphene biosensor

Drug discovery today is laborious and costly. To evaluate new drugs, most researchers test candidate compounds on expensive, complex laboratory equipment that demands special training—and testing can take days or weeks.

Biotech company Nanomedical Diagnostics offers an alternative to the resource-intensive surface plasmon resonance (SPR) and bio-layer interferometry (BLI) tools generally used today. Its novel sensing technique—featuring the world’s first commercially available graphene biosensor—lets pharmaceutical and biotherapeutics companies characterize biomolecules quickly and easily.

That capability transforms how teams work: researchers gain complete control over the characterization of their molecules, helping them make better decisions earlier in the drug discovery process.

The company’s label-free kinetic binding assay, Agile R100, is built on proprietary Field Effect Biosensing (FEB) technology—an electrical technique rather than an optical one.

Because FEB measures changes in conductance rather than changes in mass, it enables detection in complex samples and of small molecules with no lower size limit—something optical methods struggle to match.

Agile R100 · Field Effect Biosensing

An electrical technique, not an optical one

Agile R100’s intuitive open-well format means any researcher can use it without special training. At a fraction of the cost and size of competitive solutions, it brings molecular characterization within reach of far more labs.

1st
Commercially available graphene biosensor in the world
0
Lower size limit for small-molecule detection
Label-free
Kinetic binding assay—no tags or markers required
SPR/BLI
Costly optical tools FEB is designed to replace
02

The graphene challenge

Graphene offers excellent electrical conductivity, high surface area, and unique biocompatibility—potentially making it the world’s most versatile material for biosensors. Putting it into volume production is another matter.

Numerous companies have tried to commercialize graphene biosensors at scale, but integrating graphene into standard high-volume production processes has been a challenge that others could not meet. Nanomedical Diagnostics, together with Rogue Valley Microdevices, solved the riddle—overcoming major manufacturing hurdles to bring Agile R100 to market.

Run-of-the-mill graphene can’t be used for biosensors meant to generate highly sensitive results. For that kind of exceptional detection, defect-free graphene is needed—and it is exceptionally difficult to marry the low-cost world of electronics manufacturing with such a groundbreaking material. These challenges made finding the right MEMS foundry partner critical.

RVM cleanroom MEMS process flow
Integrating graphene into a high-volume MEMS process flow—without standard lithography chemistries
Why this is hard to manufacture

Defect-free material

Ordinary graphene won’t do. Highly sensitive results demand a pristine, defect-free lattice throughout the sensing surface.

Two worlds, one process

Marrying the low-cost world of electronics manufacturing with a groundbreaking new material is exceptionally difficult.

Scale, not samples

Lab demonstrations are one thing; integrating graphene growth into a repeatable, large-scale flow is another entirely.

“We knew that working with Nanomedical Diagnostics would be a challenge because there is very little information on incorporating graphene into MEMS device fabrication. But there was such great collaborative chemistry between the teams that we knew we could work through those challenges.”
Jessica Gomez  ·  Chief Executive Officer, Rogue Valley Microdevices
03

Solving for manufacturability

Traditional MEMS and CMOS fabrication relies on depositing, patterning, and etching well-understood materials. Graphene is still new—so when RVM first looked at depositing other materials on top of it, the process was an unknown.

Nanomedical Diagnostics’ requirements were particularly stringent. Exposure to some standard lithography chemistries was prohibited, and high sensitivity to solvent residue necessitated novel capping and passivation techniques. The company also required a process that would allow the integration of graphene growth to make large-scale manufacturing a reality.

Despite the unknowns, Rogue Valley Microdevices embraced the opportunity—and the two teams developed a viable, repeatable flow together.

Finished wafer of Agile R100 chips
Several hundred chips from each finished wafer
Steps in the process
Pre-processing
RVM prepares the wafers and ships them to Nanomedical Diagnostics
Graphene growth
Highest-quality graphene grown & deposited cleanly, without harsh chemicals
MEMS fabrication
RVM completes device fabrication with capping & passivation
Finished biosensors
Several hundred Agile R100 chips per wafer—ready for market
“With world-class process engineers focused on high reproducibility, quality and throughput, Rogue Valley Microdevices has been a true partner in developing a viable large-scale fabrication process for our Agile R100 biosensor chips. Because we can now manufacture graphene biosensors at scale, we can create game-changing capabilities for many life science and healthcare applications at significantly lower cost.”
Ross Bundy  ·  Founder & Chief Executive Officer, Nanomedical Diagnostics
Rogue Valley Microdevices
Your MEMS foundry partner

Fabricating the Future

Learn more about our ITAR-registered MEMS foundry services at Rogue Valley Microdevices.

943 Automation Way, Suite F
Medford, OR 97504
541‑774‑1900
sales@roguevalleymicro.com
roguevalleymicrodevices.com
ITAR-Registered MEMS Foundry · Medford, OR & Palm Bay, FLroguevalleymicrodevices.com